Therefore, different PP2A complexes have opposite role in MPN and we could speculate that is it not the same PP2A complex that is engaged upon ruxolitinib treatment as the PP2A complex that is activated by PADs. The gene discussed is PTPA; the disease is myeloproliferative neoplasm.